Your session is about to expire
← Back to Search
Nonsteroidal Anti-inflammatory Drug
Randomized to USPSTF Criteria for Prophylaxis of Preeclampsia
Phase 4
Waitlist Available
Led By Sebastian Z Ramos, MD
Research Sponsored by Women and Infants Hospital of Rhode Island
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this will be measured from 24 weeks until 39 weeks.
Awards & highlights
Study Summary
This study is evaluating whether aspirin may be more effective when given to all pregnant women, rather than only those at high risk.
Eligible Conditions
- Prophylaxis of Preeclampsia
- Medication Adherence
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ this will be measured from 24 weeks until 39 weeks.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this will be measured from 24 weeks until 39 weeks.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adherence to aspirin use
Secondary outcome measures
Fetal growth restriction
Placental abruption
Rates of postpartum hemorrhage
+1 moreTrial Design
2Treatment groups
Active Control
Group I: Randomized to USPSTF CriteriaActive Control1 Intervention
Women randomized to knowing their risk of preeclampsia and therefore, candidates for low dose aspirin.
Group II: Randomized to Universal aspirin receiptActive Control1 Intervention
Women randomized to receiving low dose aspirin without knowing their risk status.
Find a Location
Who is running the clinical trial?
Women and Infants Hospital of Rhode IslandLead Sponsor
110 Previous Clinical Trials
38,657 Total Patients Enrolled
Sebastian Z Ramos, MDPrincipal InvestigatorWomen and Infants Hospital
1 Previous Clinical Trials
30 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger